Literature DB >> 21430334

Evidence-based medicine: what it can and cannot do.

Goffredo Freddi1, José Luis Romàn-Pumar.   

Abstract

Evidence-based medicine (EBM) is not a old hat, a "cookbook" medicine perpetrated by arrogant to serve cost cutters to suppress clinical freedom, a mandatory, deterministic, totalitarian practice of medicine, a way to control cost and to ignore patient preferences, a limit to personal/ humanistic/individual medicine. EBM is a reference of excellence to guide clinical decisions, the integration of own expertise with others' expertise and patient preferences, a way to improve medical practice and limit the variability and errors created when there is not evidence to identify the gold standard and differentiate among alternatives available. But evidences need to be integrated with a new thinking based on Complexity Science. Health care systems operates as complex adaptative systems rather than rigid, linear or mechanical organizations and innovation is a critical outcome of Complexity Science. How does EBM impact drug innovation? New drug approvals are not keeping pace with rising Research and Development spending, clinical approval success rate for new chemical entities (NCEs) is progressively dropping and maybe, through these indicators, we are seeing the worst face of EBM: its limiting, blocking, and controlling side. If that is the case, EBM is the main ally to keep the economy of health systems under control and the great excuse to block the access of the innovation to patients. Certainly not the best way to maximize the benefits of EBM.

Entities:  

Mesh:

Year:  2011        PMID: 21430334     DOI: 10.4415/ANN_11_01_06

Source DB:  PubMed          Journal:  Ann Ist Super Sanita        ISSN: 0021-2571            Impact factor:   1.663


  3 in total

Review 1.  Factors predicting timely implementation of radiotherapy innovations: the first model.

Authors:  Rachelle R Swart; Maria Jg Jacobs; Cheryl Roumen; Ruud Ma Houben; Folkert Koetsveld; Liesbeth J Boersma
Journal:  Br J Radiol       Date:  2020-10-22       Impact factor: 3.039

2.  An Exploratory Analysis of Levels of Evidence for Articles Published in Indian Journal of Palliative Care in the years 2010-2011.

Authors:  Senthil Paramasivam Kumar; Vaishali Sisodia
Journal:  Indian J Palliat Care       Date:  2013-09

Review 3.  Nanopharmacology in translational hematology and oncology.

Authors:  Ciprian Tomuleasa; Cornelia Braicu; Alexandra Irimie; Lucian Craciun; Ioana Berindan-Neagoe
Journal:  Int J Nanomedicine       Date:  2014-07-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.